Aurora Cannabis Launches Physician Education Platform to Enhance Medical Cannabis Knowledge

Aurora Cannabis Enhances Physician Education with New Platform Launch

Aurora Cannabis Inc., a prominent player in the global medical cannabis industry, is making significant strides in advancing physician education through its new English-language Physician Experience Platform (PEP). This initiative, developed in collaboration with Copeia, a German healthcare technology leader, aims to bridge the knowledge gap in medical cannabis prescribing. The PEP features over 130 anonymized case studies that provide healthcare professionals with real-world insights into the application of medical cannabis in patient care, covering aspects such as patient histories, symptoms treated, therapeutic outcomes, and dosage information. By facilitating a deeper understanding of cannabis-based therapies, Aurora seeks to empower physicians and enhance the quality of patient care globally.

The launch of the English version of the PEP follows the successful introduction of its German counterpart in early 2024, underscoring Aurora's commitment to international physician education. Dr. Stephanie Lunn, Aurora's Director of Medical & Patient Affairs, emphasizes that this platform is designed to improve access to crucial clinical knowledge, thus supporting healthcare professionals in making informed prescribing decisions. The PEP not only serves as an educational resource but also aims to normalize the integration of medical cannabis into conventional healthcare practices, addressing the persistent challenges that physicians face in this emerging field.

Garvin Hirt, CEO of Copeia, recognizes that the limited incorporation of medical cannabis in standard healthcare education often hinders physicians from effectively prescribing it. By providing a comprehensive database of peer-reviewed case reports, the PEP enables clinicians to explore and compare real-world experiences, making the complexities of medical cannabis more navigable. This innovative platform signifies a pivotal moment in Aurora's strategy to reshape the landscape of medical cannabis prescribing, potentially leading to improved patient outcomes and a greater acceptance of cannabis-based therapies among healthcare providers.

In conjunction with this educational drive, Aurora Cannabis continues to bolster its market presence across Canada, Europe, Australia, and New Zealand. The company's diverse portfolio includes well-known brands such as Drift, San Rafael '71, and MedReleaf, catering to both medical and consumer markets. Furthermore, Aurora's controlling interest in Bevo Farms Ltd. positions it as a key player in the agricultural sector, enhancing its operational capabilities in the cultivation of propagated plants.

As Aurora Cannabis prepares for its participation in the H.C. Wainwright 27th Annual Global Investment Conference, the company remains focused on delivering long-term shareholder value while championing the advancement of medical cannabis education. Interested parties can access further information through the company's official website or by following Aurora on social media platforms.